Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation ...

RBC Capital analyst Luca Issi maintained a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $30.00. The ...

Undervalued biotech company Regenxbio Inc. shows promise with cutting-edge gene therapy technology for AMD and MPS II. Click ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $39.0, along ...

We offer a comprehensive suite of immune checkpoint-related products, including high-quality proteins, inhibitor screening ...

Explore our new AAV Titer ELISA and AAV Antibody Assay Kits, designed for exceptional specificity, sensitivity, and accuracy ...

Common measurements for modified adeno-associated viruses (AAVs), a gene therapy delivery method, showed substantial ...

Addgene, a purpose-driven organization helping scientists conduct experiments with greater ease, speed and reproducibility, today announced the expansion of its viral vector service with Packaged on ...

Charlestown, Massachusetts Thursday, January 9, 2025, 14:30 Hrs [IST] ...

A Danish team thinks it can aid rAAV manufacturers, who may not be able to spend three to five years working on a project with many risks.

A study published in Human Gene Therapy has involved the generation of a human monoclonal antibody (mAb) directed against human eosinophils. The heavy and light chains of that fully human anti-human ...

Figure 1: RPE65 immunocytochemistry in canine RPE cells and retinal sections. For expression studies, we divided the eyecup of the right eye of BR29 into temporal-superior, temporal-inferior ...